| Name | Title | Contact Details |
|---|
WE HELP ATHLETES PUSH LIMITS, CHALLENGE THE STATUS QUO AND STRIVE FOR THAT WHICH IS BEYOND THE HORIZON. Using insights from mountain athletes we have brought to market innovative products such as the Stretch Puffy Jacket focused on solving problems and delivering performance. SYNC is a fast growing performance sport brand building technical apparel for the mountain athlete. Through our single-mindedness and commitment to performance we have been able to deliver true innovation to our consumers.
Accelerant is a data-driven risk exchange connecting specialty insurance underwriters with risk capital providers. Founded in 2018 by a group of longtime insurance industry executives and technology experts, our vision is to rebuild the way risk is exchanged – so that it works better, for everyone. For the underwriters we call Members, we deliver a full service offering that includes insights and analytics, distribution management, operational resources, and stable underwriting capacity. Our approach frees our Members to focus on profitable underwriting while growing their businesses. Our portfolio presents attractive, validated, and diversified source of specialty insurance premium to our risk capital provider partners.
In 1990, Nitro Snowboards was founded by Thomas Delago and Sepp Ardelt in Seattle, Washington. Over the last 25 years Nitro has helped grow the sport of snowboarding through its groundbreaking product development, marketing, movies, grass roots events, and global team of world class snowboarders. Today Nitro has grown its product to offer all the essentials needed for having a good time snowboarding and traveling. Nitro´s headquarters are divided all over the world from the Mountains of Oberammergau, to the worlds best snow in Salt Lake City, UT, to the creative beaches of California, all the way up to the Northwest snowboarding destination of Vancouver, British Colombia. For more information visit us at http://www.nitrosnowboards.com or @NITROUSA on Instagram
The Federal Community Defender Office for the Eastern District of Pennsylvania, an office within the Defender Association of Philadelphia, is the designated Federal Community Defender Organization for the United States District Court for the Eastern District of Pennsylvania. Since its creation in 1972, the Federal Community Defender Office has been funded to render Defender Services to individuals who are unable to afford counsel and who are under investigation for, or charged with, violations of the laws of the United States, and to federal death-sentenced prisoners in Pennsylvania and elsewhere, when appointed. Upon appointment by the District Court or the Third Circuit Court of Appeals, the office provides representation for individuals who have been subpoenaed to appear before investigating Grand Juries, who are named defendants in criminal complaints, or who have been indicted by a Grand Jury. The representation, once undertaken, remains throughout the pendency of the proceedings, up to and including applications for relief to the Supreme Court of the United States. In addition, upon appointment, the office represents state and federal prisoners who are seeking relief by way of Habeas Corpus application in both the District Court and the Court of Appeals.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.